Analysis of lead toxicity in human cells

BMC Genomics

Volumn 13, Issue 1, 2012, Pages

  Gillis, Bruce S ^a   Arbieva, Zarema ^a   Gavin, Igor M ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Cytokines; Gene expression; Heavy metals; Lead; Peripheral blood mononuclear cells; Zinc protoporphyrin

Indexed keywords

CELL ENZYME; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; ENDOTHELIN B RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; LEAD ACETATE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; METALLOTHIONEIN; PHYTOHEMAGGLUTININ; PROTEIN KINASE; PROTOPORPHYRIN ZINC; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ADVERSE OUTCOME; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXICITY TEST; ENDOTHELIN B RECEPTOR GENE; ENZYME ACTIVITY; FEMALE; GAP JUNCTION; GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LEAD POISONING; LONG TERM EXPOSURE; MALE; NERVE CONDUCTION; NEUROPATHIC PAIN; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SYNAPTIC POTENTIAL; TRANSCRIPTION REGULATION;

ADOLESCENT; ADULT; CYTOKINES; ENVIRONMENTAL EXPOSURE; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; LEAD; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MULTIGENE FAMILY; PROTOPORPHYRINS; YOUNG ADULT;

EID: 84864185422     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/1471-2164-13-344     Document Type: Article

References (85)

1. Needleman H. Lead poisoning. Annu Rev Med 2004, 55:209-222. 10.1146/annurev.med.55.091902.103653, 14746518.
2. Philip AT, Gerson B. Lead poisoning-Part I. Incidence, etiology, and toxicokinetics. Clin Lab Med 1994, 14(2):423-444.
3. Patrick L. Lead toxicity, a review of the literature. Part 1: Exposure, evaluation, and treatment. Altern Med Rev 2006, 11(1):2-22.
4. Verstraeten SV, Aimo L, Oteiza PI. Aluminium and lead: molecular mechanisms of brain toxicity. Arch Toxicol 2008, 82(11):789-802. 10.1007/s00204-008-0345-3, 18668223.
5. Mudipalli A. Lead hepatotoxicity & potential health effects. Indian J Med Res 2007, 126(6):518-527.
6. Bressler J, Kim KA, Chakraborti T, Goldstein G. Molecular mechanisms of lead neurotoxicity. Neurochem Res 1999, 24(4):595-600. 10.1023/A:1022596115897, 10227691.
7. Marchetti C. Molecular targets of lead in brain neurotoxicity. Neurotox Res 2003, 5(3):221-236. 10.1007/BF03033142, 12835126.
8. Toscano CD, Guilarte TR. Lead neurotoxicity: from exposure to molecular effects. Brain Res Brain Res Rev 2005, 49(3):529-554.
9. Patrick L. Lead toxicity part II: the role of free radical damage and the use of antioxidants in the pathology and treatment of lead toxicity. Altern Med Rev 2006, 11(2):114-127.
10. Gurer H, Ercal N. Can antioxidants be beneficial in the treatment of lead poisoning?. Free Radic Biol Med 2000, 29(10):927-945. 10.1016/S0891-5849(00)00413-5, 11084283.
11. Bechara EJ. Oxidative stress in acute intermittent porphyria and lead poisoning may be triggered by 5-aminolevulinic acid. Braz J Med Biol Res 1996, 29(7):841-851.
12. Adonaylo VN, Oteiza PI. Pb2+ promotes lipid oxidation and alterations in membrane physical properties. Toxicology 1999, 132(1):19-32. 10.1016/S0300-483X(98)00134-6, 10199578.
13. Adonaylo VN, Oteiza PI. Lead intoxication: antioxidant defenses and oxidative damage in rat brain. Toxicology 1999, 135(2-3):77-85.
14. Roots LM. Tests available for assessing recent exposure to inorganic lead compounds and their use for screening purposes. Sci Total Environ 1979, 11(1):59-68. 10.1016/0048-9697(79)90033-0, 84406.
15. Blood lead levels in young children--United States and selected states, 1996-1999. MMWR Morb Mortal Wkly Rep 2000, 49(50):1133-1137.
16. Rabinowitz MB, Wetherill GW, Kopple JD. Kinetic analysis of lead metabolism in healthy humans. J Clin Invest 1976, 58(2):260-270. 10.1172/JCI108467, 333178, 783195.
17. Labbe RF, Vreman HJ, Stevenson DK. Zinc protoporphyrin: A metabolite with a mission. Clin Chem 1999, 45(12):2060-2072.
18. Staudinger KC, Roth VS. Occupational lead poisoning. Am Fam Physician 1998, 57(4):719-726. 731-712.
19. Martin CJ, Werntz CL, Ducatman AM. The interpretation of zinc protoporphyrin changes in lead intoxication: a case report and review of the literature. Occup Med (Lond) 2004, 54(8):587-591.
20. Kansky A. Fluorescence microscopy test in porphyrias, photodermatoses and lead exposed persons. Arch Dermatol Forsch 1975, 252(4):311-315.
21. Gillis B, Gavin IM, Arbieva Z, King ST, Jayaraman S, Prabhakar BS. Identification of human cell responses to benzene and benzene metabolites. Genomics 2007, 90(3):324-333. 10.1016/j.ygeno.2007.05.003, 17572062.
22. Gavin IM, Gillis B, Arbieva Z, Prabhakar BS. Identification of human cell responses to hexavalent chromium. Environ Mol Mutagen 2007, 48(8):650-657. 10.1002/em.20331, 17685462.
23. Kratz A, Ferraro M, Sluss PM, Lewandrowski KB. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Laboratory reference values. N Engl J Med 2004, 351(15):1548-1563. 10.1056/NEJMcpc049016, 15470219.
24. Lawrence DA. Heavy metal modulation of lymphocyte activities--II. Lead, an in vitro mediator of B-cell activation. Int J Immunopharmacol 1981, 3(2):153-161. 10.1016/0192-0561(81)90006-0, 6266971.
25. Razani-Boroujerdi S, Edwards B, Sopori ML. Lead stimulates lymphocyte proliferation through enhanced T cell-B cell interaction. J Pharmacol Exp Ther 1999, 288(2):714-719.
26. Warner GL, Lawrence DA. Stimulation of murine lymphocyte responses by cations. Cell Immunol 1986, 101(2):425-439. 10.1016/0008-8749(86)90155-3, 3489539.
27. De Guise S, Bernier J, Lapierre P, Dufresne MM, Dubreuil P, Fournier M. Immune function of bovine leukocytes after in vitro exposure to selected heavy metals. Am J Vet Res 2000, 61(3):339-344. 10.2460/ajvr.2000.61.339, 10714530.
28. Coyle P, Philcox JC, Carey LC, Rofe AM. Metallothionein: The multipurpose protein. Cellular and Molecular Life Sciences 2002, 59(4):627-647. 10.1007/s00018-002-8454-2, 12022471.
29. Haq F, Mahoney M, Koropatnick J. Signaling events for metallothionein induction. Mutat Res 2003, 533(1-2):211-226.
30. Klaassen CD, Liu J. Role of metallothionein in cadmium-induced hepatotoxicity and nephrotoxicity. Drug Metabolism Reviews 1997, 29(1-2):79-102.
31. Lanphear BP, Dietrich K, Auinger P, Cox C. Cognitive deficits associated with blood lead concentrations <10 microg/dL in US children and adolescents. Public Health Rep 2000, 115(6):521-529. 10.1093/phr/115.6.521, 1308622, 11354334.
32. Canfield RL, Henderson CR, Cory-Slechta DA, Cox C, Jusko TA, Lanphear BP. Intellectual impairment in children with blood lead concentrations below 10 microg per deciliter. N Engl J Med 2003, 348(16):1517-1526. 10.1056/NEJMoa022848, 12700371.
33. Cory-Slechta DA. Relationships between Pb-induced changes in neurotransmitter system function and behavioral toxicity. Neurotoxicology 1997, 18(3):673-688.
34. La P, Fernando AP, Wang Z, Salahudeen A, Yang G, Lin Q, Wright CJ, Dennery PA. Zinc protoporphyrin regulates cyclin D1 expression independent of heme oxygenase inhibition. J Biol Chem 2009, 284(52):36302-36311. 10.1074/jbc.M109.031641, 2794746, 19850937.
35. Hopkins SJ. The pathophysiological role of cytokines. Leg Med (Tokyo) 2003, 5(Suppl 1):S45-S57.
36. Heo Y, Parsons PJ, Lawrence DA. Lead differentially modifies cytokine production in vitro and in vivo. Toxicol Appl Pharmacol 1996, 138(1):149-157. 10.1006/taap.1996.0108, 8658504.
37. Iavicoli I, Marinaccio A, Castellino N, Carelli G. Altered cytokine production in mice exposed to lead acetate. Int J Immunopathol Pharmacol 2004, 17(2 Suppl):97-102.
38. Iavicoli I, Carelli G, Stanek EJ, Castellino N, Calabrese EJ. Below background levels of blood lead impact cytokine levels in male and female mice. Toxicol Appl Pharmacol 2006, 210(1-2):94-99.
39. Lahat N, Shapiro S, Froom P, Kristal-Boneh E, Inspector M, Miller A. Inorganic lead enhances cytokine-induced elevation of matrix metalloproteinase MMP-9 expression in glial cells. J Neuroimmunol 2002, 132(1-2):123-128.
40. Struzynska L, Dabrowska-Bouta B, Koza K, Sulkowski G. Inflammation-like glial response in lead-exposed immature rat brain. Toxicol Sci 2007, 95(1):156-162.
41. White LD, Cory-Slechta DA, Gilbert ME, Tiffany-Castiglioni E, Zawia NH, Virgolini M, Rossi-George A, Lasley SM, Qian YC, Basha MR. New and evolving concepts in the neurotoxicology of lead. Toxicol Appl Pharmacol 2007, 225(1):1-27. 10.1016/j.taap.2007.08.001, 17904601.
42. Guo TL, Mudzinski SP, Lawrence DA. The heavy metal lead modulates the expression of both TNF-alpha and TNF-alpha receptors in lipopolysaccharide-activated human peripheral blood mononuclear cells. J Leukoc Biol 1996, 59(6):932-939.
43. Di Lorenzo L, Vacca A, Corfiati M, Lovreglio P, Soleo L. Evaluation of tumor necrosis factor-alpha and granulocyte colony-stimulating factor serum levels in lead-exposed smoker workers. Int J Immunopathol Pharmacol 2007, 20(2):239-247.
44. Bebianno MJ, Cravo A, Miguel C, Morais S. Metallothionein concentrations in a population of Patella aspera: variation with size. Sci Total Environ 2003, 301(1-3):151-161.
45. Carvalho CD, de Araujo HSS, Fernandes MN. Hepatic metallothionein in a teleost (Prochilodus scrofa) exposed to copper at pH 4.5 and pH 8.0. Comparative Biochemistry and Physiology B-Biochemistry & Molecular Biology 2004, 137(2):225-234.
46. Domouhtsidou GP, Dailianis S, Kaloyianni M, Dimitriadis VK. Lysosomal membrane stability and metallothionein content in Mytilus galloprovincialis (L.), as biomarkers - Combination with trace metal concentrations. Mar Pollut Bull 2004, 48(5-6):572-586.
47. Geret F, Jouan A, Turpin V, Bebianno MJ, Cosson RP. Influence of metal exposure on metallothionein synthesis and lipid peroxidation in two bivalve mollusks: the oyster (Crassostrea gigas) and the mussel (Mytilus edulis). Aquatic Living Resources 2002, 15(1):61-66.
48. Lecoeur S, Videmann B, Berny P. Evaluation of metallothionein as a biomarker of single and combined Cd/Cu exposure in Dreissena polymorpha. Environ Res 2004, 94(2):184-191. 10.1016/S0013-9351(03)00069-0, 14757381.
49. Lukkari T, Taavitsainen M, Soimasuo M, Oikari A, Haimi J. Biomarker responses of the earthworm Aporrectodea tuberculata to copper and zinc exposure: differences between populations with and without earlier metal exposure. Environ Pollut 2004, 129(3):377-386. 10.1016/j.envpol.2003.12.008, 15016459.
50. Perceval O, Pinel-Alloul B, Methot G, Couillard Y, Giguere A, Campbell PGC, Hare L. Cadmium accumulation and metallothionein synthesis in freshwater bivalves (Pyganodon grandis): relative influence of the metal exposure gradient versus limnological variability. Environ Pollut 2002, 118(1):5-17. 10.1016/S0269-7491(01)00282-2, 11996382.
51. Regoli F, Pellegrini D, Winston GW, Gorbi S, Giuliani S, Virno-Lamberti C, Bomdadre S. Application of biomarkers for assessing the biological impact of dredged materials in the Mediterranean: the relationship between antioxidant responses and susceptibility to oxidative stress in the red mullet (Mullus barbatus). Mar Pollut Bull 2002, 44(9):912-922. 10.1016/S0025-326X(02)00120-0, 12405216.
52. Shea J, Moran T, Dehn PF. A bioassay for metals utilizing a human cell line. Toxicol Vitr 2008, 22(4):1025-1031.
53. Lu J, Jin TY, Nordberg G, Nordberg M. Metallothionein gene expression in peripheral lymphocytes from cadmium-exposed workers. Cell Stress & Chaperones 2001, 6(2):97-104. 10.1379/1466-1268(2001)006<0097:MGEIPL>2.0.CO;2, 22905257.
54. Vaziri ND, Sica DA. Lead-induced hypertension: role of oxidative stress. Curr Hypertens Rep 2004, 6(4):314-320. 10.1007/s11906-004-0027-3, 15257867.
55. Lob S, Konigsrainer A, Rammensee HG, Opelz G, Terness P. Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?. Nat Rev Cancer 2009, 9(6):445-452. 10.1038/nrc2639, 19461669.
56. Katz JB, Muller AJ, Prendergast GC. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol Rev 2008, 222:206-221. 10.1111/j.1600-065X.2008.00610.x, 18364004.
57. Mishra KP. Lead exposure and its impact on immune system: a review. Toxicol In Vitro 2009, 23(6):969-972. 10.1016/j.tiv.2009.06.014, 19540334.
58. Fischbein A, Tsang P, Luo JC, Roboz JP, Jiang JD, Bekesi JG. Phenotypic aberrations of CD3+ and CD4+ cells and functional impairments of lymphocytes at low-level occupational exposure to lead. Clin Immunol Immunopathol 1993, 66(2):163-168. 10.1006/clin.1993.1020, 8095868.
59. Undeger U, Basaran N, Canpinar H, Kansu E. Immune alterations in lead-exposed workers. Toxicology 1996, 109(2-3):167-172.
60. Li S, Zhengyan Z, Rong L, Hanyun C. Decrease of CD4+ T-lymphocytes in children exposed to environmental lead. Biol Trace Elem Res 2005, 105(1-3):19-25.
61. Muller N, Myint AM, Schwarz MJ. The impact of neuroimmune dysregulation on neuroprotection and neurotoxicity in psychiatric disorders-relation to drug treatment. Dialogues Clin Neurosci 2009, 11(3):319-332. 3181925, 19877499.
62. Miller CL, Llenos IC, Dulay JR, Barillo MM, Yolken RH, Weis S. Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia. Neurobiol Dis 2004, 15(3):618-629. 10.1016/j.nbd.2003.12.015, 15056470.
63. Jin Y, Duan L, Lee SH, Kloosterboer HJ, Blair IA, Penning TM. Human cytosolic hydroxysteroid dehydrogenases of the aldo-ketoreductase superfamily catalyze reduction of conjugated steroids: implications for phase I and phase II steroid hormone metabolism. J Biol Chem 2009, 284(15):10013-10022. 10.1074/jbc.M809465200, 2665056, 19218247.
64. Penning TM, Byrns MC. Steroid hormone transforming aldo-keto reductases and cancer. Ann N Y Acad Sci 2009, 1155:33-42. 10.1111/j.1749-6632.2009.03700.x, 3038333, 19250190.
65. Zheng P. Neuroactive steroid regulation of neurotransmitter release in the CNS: action, mechanism and possible significance. Prog Neurobiol 2009, 89(2):134-152. 10.1016/j.pneurobio.2009.07.001, 19595736.
66. Frye CA. Neurosteroids' effects and mechanisms for social, cognitive, emotional, and physical functions. Psychoneuroendocrinology 2009, 34(Suppl 1):S143-S161. 2898141, 19656632.
67. Glahn F, Schmidt-Heck W, Zellmer S, Guthke R, Wiese J, Golka K, Hergenroder R, Degen GH, Lehmann T, Hermes M, et al. Cadmium, cobalt and lead cause stress response, cell cycle deregulation and increased steroid as well as xenobiotic metabolism in primary normal human bronchial epithelial cells which is coordinated by at least nine transcription factors. Arch Toxicol 2008, 82(8):513-524. 10.1007/s00204-008-0331-9, 18654764.
68. Tai HH, Ensor CM, Tong M, Zhou H, Yan F. Prostaglandin catabolizing enzymes. Prostaglandins Other Lipid Mediat 2002, 68-69:483-493. 2844927, 19545642.
69. Murphy RC, Gijon MA. Biosynthesis and metabolism of leukotrienes. Biochem J 2007, 405(3):379-395. 10.1042/BJ20070289, 17623009.
70. Hong CS, Kwon SJ, Kim do H. Multiple functions of junctin and junctate, two distinct isoforms of aspartyl beta-hydroxylase. Biochem Biophys Res Commun 2007, 362(1):1-4. 10.1016/j.bbrc.2007.07.166, 17706594.
71. Hsieh JY, Chen SH, Hung HC. Functional roles of the tetramer organization of malic enzyme. J Biol Chem 2009, 284(27):18096-18105. 10.1074/jbc.M109.005082, 2709377, 19416979.
72. Vasiliou V, Pappa A. Polymorphisms of human aldehyde dehydrogenases. Consequences for drug metabolism and disease. Pharmacology 2000, 61(3):192-198.
73. Gelbman BD, Heguy A, O'Connor TP, Zabner J, Crystal RG. Upregulation of pirin expression by chronic cigarette smoking is associated with bronchial epithelial cell apoptosis. Respir Res 2007, 8:10. 10.1186/1465-9921-8-10, 1805431, 17288615.
74. Daigle ND, Carpentier GA, Frenette-Cotton R, Simard MG, Lefoll MH, Noel M, Caron L, Noel J, Isenring P. Molecular characterization of a human cation-Cl- cotransporter (SLC12A8A, CCC9A) that promotes polyamine and amino acid transport. J Cell Physiol 2009, 220(3):680-689. 10.1002/jcp.21814, 19472210.
75. Kanai Y, Endou H. Heterodimeric amino acid transporters: molecular biology and pathological and pharmacological relevance. Curr Drug Metab 2001, 2(4):339-354. 10.2174/1389200013338324, 11766986.
76. Sturm RA. Molecular genetics of human pigmentation diversity. Hum Mol Genet 2009, 18(R1):R9-R17. 10.1093/hmg/ddp003, 19297406.
77. Rapley EA, Nathanson KL. Predisposition alleles for testicular germ cell tumour. Curr Opin Genet Dev 2010, 20:1-6. 10.1016/j.gde.2010.01.001, 20116234.
78. Patwari P, Chutkow WA, Cummings K, Verstraeten VL, Lammerding J, Schreiter ER, Lee RT. Thioredoxin-independent regulation of metabolism by the alpha-arrestin proteins. J Biol Chem 2009, 284(37):24996-25003. 10.1074/jbc.M109.018093, 2757204, 19605364.
79. Tian Y, Green PG, Stamova B, Hertz-Picciotto I, Pessah IN, Hansen R, Yang X, Gregg JP, Ashwood P, Jickling G, Van de Water J, Sharp FR. Correlations of gene expression with blood lead levels in children with autism compared to typically developing controls. Neurotox Res 2011, 19(1):1-13. 10.1007/s12640-009-9126-x, 3006638, 19921347.
80. Labbe RF. Clinical utility of zinc protoporphyrin. Clin Chem 1992, 38(11):2167-2168.
81. de la Fuente H, Portales-Perez D, Baranda L, Diaz-Barriga F, Saavedra-Alanis V, Layseca E, Gonzalez-Amaro R. Effect of arsenic, cadmium and lead on the induction of apoptosis of normal human mononuclear cells. Clin Exp Immunol 2002, 129(1):69-77. 10.1046/j.1365-2249.2002.01885.x, 1906410, 12100024.
82. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003, 4(2):249-264. 10.1093/biostatistics/4.2.249, 12925520.
83. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society, Series B 1995, 57:289-300.
84. DAVID functional annotation tool http://david.abcc.ncifcrf.gov.
85. Gene Expression Omnibus http://www.ncbi.nlm.nih.gov/projects/geo/.